Treprostinil (Orenitram) vs Treprostinil (Remodulin)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline
Treprostinil (Orenitram)
Marketed by United Therapeutics
NCT00325403 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 349 participants enrolled and 228 included in the prespecified primary analysis. The clinical primary endpoint was met: oral treprostinil produced a statistically significant placebo-corrected improvement in six-minute walk distance at Week 12.
Reported efficacy
Six Minute Walk Distance (6MWD) (Baseline and Week 12): Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49) (met)
Result source: NCT00325403
Treprostinil (Remodulin)
Marketed by United Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT06317805 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Pulmonary Arterial Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Treprostinil (Orenitram): 5 of 5 rows · Treprostinil (Remodulin): 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Treprostinil (Orenitram) | Treprostinil (Remodulin) |
|---|---|---|
| 6MWD - Change absolute change · m No placebo or comparator arm | 2.7 m @ 24wka,b,c,d NCT02276872 · Phase 2 · registry result, not featured evidence show 2 more doses22.1 m @ 24wk NCT02276872 · Phase 2 · registry result, not featured evidence 12.8 m @ 24wk NCT02276872 · Phase 2 · registry result, not featured evidence · combination | 440.8 mb,c,d NCT03055221 · Phase 4 · registry result, not featured evidence |
| Dropout rate | 21.9%e NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 7 more results42.1% NCT01560637 · Phase 3 · registry result, not featured evidence 76.7% NCT01027949 · Phase 3 · registry result, not featured evidence 57.2% NCT01560624 · Phase 3 · registry result, not featured evidence 12.1% NCT00325442 · Phase 3 · registry result, not featured evidence 10%Cohort 1 (Transitioning From Paren NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 2 (Transitioning From Inhal NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 3 (Add-on to Current PAH Th NCT02276872 · Phase 2 · registry result, not featured evidence · combination | n/a: no completion milestonef NCT03055221 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | —e NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 7 more results13.4% NCT01560637 · Phase 3 · registry result, not featured evidence 19.2% NCT01027949 · Phase 3 · registry result, not featured evidence — NCT01560624 · Phase 3 · registry result, not featured evidence — NCT00325442 · Phase 3 · registry result, not featured evidence 10%Cohort 1 (Transitioning From Paren NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 2 (Transitioning From Inhal NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 3 (Add-on to Current PAH Th NCT02276872 · Phase 2 · registry result, not featured evidence · combination | 10%f NCT03055221 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 17.9%e NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 7 more results43.8% NCT01560637 · Phase 3 · registry result, not featured evidence 61.2% NCT01027949 · Phase 3 · registry result, not featured evidence 33.5% NCT01560624 · Phase 3 · registry result, not featured evidence 18.4% NCT00325442 · Phase 3 · registry result, not featured evidence 50%Cohort 1 (Transitioning From Paren NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 2 (Transitioning From Inhal NCT02276872 · Phase 2 · registry result, not featured evidence 33.3%Cohort 3 (Add-on to Current PAH Th NCT02276872 · Phase 2 · registry result, not featured evidence · combination | 87.5%f NCT03055221 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | e headache 62.9% (placebo 19.5%) diarrhea 30.5% (placebo 15.6%) nausea 29.8% (placebo 18.2%) NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 7 more resultsheadache 69.8% diarrhoea 66.2% flushing 42.8% NCT01560637 · Phase 3 · registry result, not featured evidence headache 78.1% diarrhoea 66.2% nausea 56.5% NCT01027949 · Phase 3 · registry result, not featured evidence headache 74.9% (placebo 34.9%) diarrhoea 69.4% (placebo 28.5%) flushing 44.5% (placebo 7.8%) NCT01560624 · Phase 3 · registry result, not featured evidence headache 86.2% (placebo 36.9%) nausea 64.4% (placebo 34.1%) diarrhea 60.9% (placebo 27.3%) NCT00325442 · Phase 3 · registry result, not featured evidence headache 100% diarrhoea 75% nausea 75% NCT02276872 · Phase 2 · registry result, not featured evidence · combination | f abdominal discomfort 18.8% catheter site pain 18.8% cough 18.8% NCT03055221 · Phase 4 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2 versus Phase 4.
- cPopulation comparability has not been reviewed for both studies.
- dThe assessment timepoint is not available for both results.
- ePopulation comparability has not been reviewed for 7 of these studies.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Treprostinil (Orenitram)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
+ 17 further endpoints in the CSV export.
Treprostinil (Remodulin)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Treprostinil (Orenitram)'s landscape · Treprostinil (Remodulin)'s landscape